Outcomes of endovascular salvage of clotted arteriovenous access and predictors of patency after thrombectomy

Clinical outcomes following the surgery of new autologous arteriovenous fistulas proximal to the failed ones in end-stage renal disease patients: a retrospective cohort study

“…Therefore, from the opinion of the protection of vascular access resource, if patients can obtain the most benefits from the surgery of new AVF proximal to the failed ones need further research. Center experience is considered of major importance in choosing an appropriate standard of care to reduce the AVF failure rate and to improve the successful rate of restored AVF [14]. Further appropriately powered and randomized studies are still needed to clarifying this important issue.…”

“…The surgery of new AVF proximal to the failed ones is the traditional treatment for restoring failed AVF and is also inexpensive in China. Therefore, dialysis units should evaluate an appropriate standard of care to reduce the AVF failure rate and to improve the successful rate of restored AVF [14]. Accordingly, we conducted a retrospective cohort study to evaluate the clinical outcomes of the surgery of new AVF proximal to the failed forearm AVF.…”

The Cleaner XT™ Device as an Endovascular Adjunct for Pharmacomechanical Thrombolysis of Thrombosed Arteriovenous Fistulas and Grafts

“…The procedure was performed according to our previously described centre protocol. 13,14) Briefly, antegrade and retrograde vascular sheaths/cannulae were placed in the thrombosed AVG/AVF under ultrasound guidance. The thrombolytic agent choices and doses were at the operator s discretion.…”

Single-Center Prospective Pilot Study of Sirolimus Drug-Coated Balloon Angioplasty in Maintaining the Patency of Thrombosed Arteriovenous Graft

“…Although pharmacomechanical thrombectomy of a thrombosed AVG is associated with a high technical success rate, its long-term patency remains poor, and repeated interventions are often required to maintain its patency (10,14). The average reported rates of 3-and 6-month primary patency for management with pharmacologic thrombolysis or mechanical thrombectomy are only 49% and 38%, respectively (14).…”

“…Specifically, patients with thrombosed AVGs were excluded from all the RCTs. Although the use of paclitaxel DCB at the graft vein junction has been shown in 1 of the RCTs to improve the absolute target lesion and circuit primary patency at 6 months by 32% and 27%, respectively, in nonthrombosed AVG (9), a separate retrospective analysis of the use of paclitaxel DCB in patients with thrombosed AVG showed that they continued to fare poorly, with 6-month circuit patency rates of only 23% (10). Hence, there is much potential for improvement in the patency rate of thrombosed AVG after successful thrombectomy.…”